DPP4 and scleroderma: While DPP4 inhibitors are clinically deployed for diabetes, our data expand their therapeutic relevance to CD-related intestinal stricture, a concept supported by preclinical studies in scleroderma, diabetic nephropathy, pulmonary and hepatic fibrosis.11